2019-04-26MMMM D, YYYY

First Quarter 2019 Results

At a glance

Jean-Baptiste de Chatillon
2019-04-30MMMM D, YYYY

Annual General Meeting 2019

Find all information about the Annual General Meeting 2019

Upcoming events

  • 2019-06-11
  • 2019-06-12
All financial results going back to 2013

All financial results going back to 2013

Annual Report on Form 20-F 2018

Annual Report on Form 20-F 2018

Contact the Investor Relations team

54 rue La Boétie
75008 Paris FRANCE
France +33 (0)1 53 77 45 45 •
United States +1 908 981 5560

Press releases

[Feed JS]

In-depth reading

Young boy on a bicycle

New franchise Rare Blood Disorders

In 2018, Sanofi created a leading platform in Rare Blood Disorders through a series of three strategic deals: we obtained global rights for fitusiran, acquired Bioverativ and Ablynx. These operations should expand Sanofi’s presence in Specialty Care and further strengthen our Research & Development pipeline.
Digital factory

The digital revolution

2017 Integrated Report

2018 Integrated Report


2018 sales reflecting 2019 GBU structure

2019-02-07MMMM D, YYYY

IR conference call on Odyssey Outcomes

2018-03-10MMMM D, YYYY

Individual shareholders

Direct access to Individual shareholders - Welcome to Sanofi

Access your dedicated section

Shareholder Handbook 2019

Two Asian women

Letter to shareholders March 2019

Sanofi IR app on different devices

SANOFI IR The Investor Relations app

SANOFI IR provides financial information with direct access to key news, events, publications and a dedicated section for individual shareholders
Download the IR app on the App Store Get the IR app on Google Play